Brivaracetam en dolor neuropático: evidencia preclínica y primeros datos clínicos.
Saved in:
| Title: | Brivaracetam en dolor neuropático: evidencia preclínica y primeros datos clínicos. |
|---|---|
| Alternate Title: | Brivaracetam in neuropathic pain: preclinical evidence and early clinical data. |
| Authors: | Alcántara-Montero, Antonio1 (AUTHOR) a.alcantara.montero@hotmail.com |
| Source: | Dolor: Investigación, Clínica & Terapéutica. 2026, Vol. 41 Issue 2, p47-52. 6p. |
| Subjects: | Anticonvulsants, Analgesic effectiveness, Synaptic vesicles, Clinical trials, Ion channels, Neuralgia |
| Abstract (English): | Brivaracetam, a third-generation antiepileptic drug, has garnered increasing interest as a potential therapeutic alternative for the treatment of neuropathic pain. Unlike its precursor, levetiracetam, it exhibits markedly higher affinity for synaptic vesicle protein 2A and also acts on ion channels involved in neuronal hyperexcitability. Although its approved indication is currently limited to seizure control, various preclinical studies and preliminary clinical observations suggest an analgesic potential that remains insufficiently explored. This narrative review examines the underlying mechanisms of action, summarizes findings from both animal and human models, and contextualizes the emerging role of brivaracetam as a pharmacological candidate in the management of neuropathic pain. The still preliminary evidence underscores the need for specific clinical trials to confirm its efficacy and safety profile in this novel therapeutic domain. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Brivaracetam, un antiepiléptico de tercera generación, ha despertado un creciente interés como posible alternativa terapéutica en el tratamiento del dolor neuropático. A diferencia de su precursor, levetiracetam, posee una afinidad marcadamente superior por la proteína vesicular sináptica 2A y actúa además sobre canales iónicos relacionados con la hiperexcitabilidad neuronal. Aunque su uso aprobado se limita actualmente al control de crisis epilépticas, diversos estudios preclínicos y observaciones clínicas preliminares apuntan a un potencial efecto analgésico aún insuficientemente explorado. Esta revisión narrativa examina los mecanismos de acción implicados, resume los hallazgos obtenidos en modelos animales y humanos, y contextualiza el papel emergente de brivaracetam como candidato farmacológico en el abordaje del dolor neuropático. La evidencia, todavía incipiente, subraya la necesidad de ensayos clínicos específicos que confirmen su eficacia y perfil de seguridad en este nuevo campo terapéutico. [ABSTRACT FROM AUTHOR] |
| Copyright of Dolor: Investigación, Clínica & Terapéutica is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Brivaracetam, a third-generation antiepileptic drug, has garnered increasing interest as a potential therapeutic alternative for the treatment of neuropathic pain. Unlike its precursor, levetiracetam, it exhibits markedly higher affinity for synaptic vesicle protein 2A and also acts on ion channels involved in neuronal hyperexcitability. Although its approved indication is currently limited to seizure control, various preclinical studies and preliminary clinical observations suggest an analgesic potential that remains insufficiently explored. This narrative review examines the underlying mechanisms of action, summarizes findings from both animal and human models, and contextualizes the emerging role of brivaracetam as a pharmacological candidate in the management of neuropathic pain. The still preliminary evidence underscores the need for specific clinical trials to confirm its efficacy and safety profile in this novel therapeutic domain. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 02140659 |
| DOI: | 10.24875/DOL.M25000031 |
